Delivery Order SPE2DB25D3005-SPE2DB25FQHUG
- Not listed
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Gilenya 0.5 mg capsules in a quantity of 30 units. This is a firm fixed price delivery order with no set-aside designation, valued at $25,513.12 and scheduled for completion by August 12, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $77,327.57 to AmerisourceBergen Drug Corp for the supply of Gilenya 0.5 mg capsules (30-count packaging) on July 28, 2025. This competitively awarded, firm fixed-price delivery order, which is not subject to any set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Gilenya 0.5 mg capsules (30-count units) with a ceiling value of $20,252.06. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is set for ultimate completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $26,448.92 contract is for the supply of Gilenya 0.5 mg capsules, a specialty pharmaceutical product. The delivery order was issued under an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that serves as the primary vehicle for Amerisourcebergen to...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,019.86, is for the delivery of Gilenya 0.5 mg capsules with an ultimate completion date of April 29, 2025. The contract is a firm fixed-price delivery order and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
- Amerisourcebergen Drug Corp has been awarded a $16,359.50 firm fixed price delivery order contract to supply Gilenya 0.5 mg capsules to the Defense Logistics Agency Troop Support Medical. Under this contract, the vendor will deliver 30 capsules of Gilenya to the place of performance in Conshohocken, Pennsylvania by the completion date of October 12, 2023. The prime contractor is a subsidiary of Amerisourcebergen Corporation. No set-aside designation was used for this award to supply...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,597.07, is for the supply of Gilenya 0.5 mg capsules. The contract has an ultimate completion date of July 17, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This delivery order for $16,576.54 was awarded by the Defense Logistics Agency to Amerisourcebergen Drug Corp on October 19, 2023 for the delivery of 4562539121 Gilenya 0.5 mg capsules, 30 count. The order has a firm fixed price and calls for delivery to be completed by October 20, 2023 to a location in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. As the Defense Logistics Agency is responsible for worldwide logistics support of the U.S. Department of...
- This is a delivery order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $9,952.07 firm fixed price contract is for the supply of Gilenya 0.5 mg capsules, a specialty medication used for the treatment of multiple sclerosis. The contract has an ultimate completion date of September 16, 2024 and was awarded on September 13, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a...
- The Defense Logistics Agency awarded a $2,989.64 firm fixed price delivery order to Amerisourcebergen Drug Corp for 30 capsules of the 0.5 mg dosage of Gilenya to treat multiple sclerosis. Amerisourcebergen Drug Corp will deliver the pharmaceutical products to a location in Conshohocken, Pennsylvania by July 3, 2023 under the terms of the order. The prime contractor, Amerisourcebergen Drug Corp, is a division of Amerisourcebergen Corporation, a major pharmaceutical distributor and services...
- SPE2DB25D3005Indefinite Delivery Contract
- SPE2DB25D3005-SPE2DB25FQHUGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,630.00 to AmerisourceBergen Drug Corp for the supply of Gilenya 0.5 mg capsules (quantity: 30 units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Gilenya (fingolimod) is a disease-modifying therapy used in the treatment of multiple sclerosis, reflecting the Defense Logistics Agency's ongoing role in supplying specialized pharmaceutical products to support military healthcare systems. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities through its comprehensive global pharmaceutical support vehicle, which encompasses brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.6k | 8/12/25 |